EMERGENT BIOSOLUTIONS INC (EBS) Stock News

USA - New York Stock Exchange - NYSE:EBS - US29089Q1058 - Common Stock

11.17 USD

+0.12 (+1.09%)

Last: 11/28/2025, 8:25:15 PM

11.24 USD

+0.07 (+0.63%)

After Hours: 11/28/2025, 8:25:15 PM

Technical Analysis

Fundamental Analysis

Analyst Ratings

Earnings Estimates

EBS Latest News, Press Relases and Analysis

All

Press Releases

11 days ago - By: Emergent BioSolutions

Emergent BioSolutions Marks 10-Year Anniversary of the U.S. FDA Approval of NARCAN® Nasal Spray and Reinforces its Commitment to Increasing Naloxone Access

17 days ago - By: Emergent BioSolutions

Emergent BioSolutions Announces Retirement of Dr. Louis W. Sullivan from Board of Directors

17 days ago - By: Emergent BioSolutions

Emergent BioSolutions Announces Retirement of Dr. Louis W. Sullivan from Board of Directors

17 days ago - By: Zacks Investment Research - Mentions: BDTX

Black Diamond Therapeutics, Inc. (BDTX) Hits Fresh High: Is There Still Room to Run?

a month ago - By: Benzinga - Mentions: CGO ROL ESRT NNBR ...

Earnings Scheduled For October 29, 2025

22 days ago - By: Zacks Investment Research

Looking for a Fast-paced Momentum Stock at a Bargain? Consider Emergent Biosolutions (EBS)

a month ago - By: Zacks Investment Research - Mentions: VCEL

Emergent Biosolutions Inc. (EBS) Soars to 52-Week High, Time to Cash Out?

a month ago - By: The Motley Fool

Emergent BioSolutions (EBS) Earnings Transcript

a month ago - By: Benzinga - Mentions: HBIO IART GH INTS ...

12 Health Care Stocks Moving In Thursday's Intraday Session

a month ago - By: Stocktwits

Retail Traders Turn Ultra-Bullish On Emergent BioSolutions After Surprise Q3 Profit

a month ago - By: Zacks Investment Research - Mentions: NTLA

Emergent Biosolutions (EBS) Beats Q3 Earnings and Revenue Estimates

a month ago - By: Emergent BioSolutions

Emergent BioSolutions Reports Third Quarter 2025 Financial Results

a month ago - By: Emergent BioSolutions

Emergent BioSolutions Reports Third Quarter 2025 Financial Results

a month ago - By: Emergent BioSolutions

Emergent BioSolutions Releases New Survey Findings Revealing Heightened Concerns About Biological Threats and U.S. Preparedness

2 months ago - By: Emergent BioSolutions

Emergent BioSolutions to Report Third Quarter 2025 Financial Results on October 29, 2025

2 months ago - By: Emergent BioSolutions

Emergent BioSolutions to Report Third Quarter 2025 Financial Results on October 29, 2025

2 months ago - By: Emergent BioSolutions

Emergent BioSolutions Recognizes Several Important Observances to Help Save Lives from Opioid Poisoning and Encourages Preparedness with Life-Saving Naloxone

2 months ago - By: Emergent BioSolutions

Emergent BioSolutions Recognizes Several Important Observances to Help Save Lives from Opioid Poisoning and Encourages Preparedness with Life-Saving Naloxone

2 months ago - By: Stocktwits - Mentions: IWMW AVSU

Emergent BioSolutions Stock Rises After Receiving Fresh International Purchase Orders: Retail Says Stock Is ‘Significantly Undervalued’

2 months ago - By: Emergent BioSolutions

Emergent BioSolutions Secures $29 Million in MCM Product Orders from International Government Partner

2 months ago - By: Emergent BioSolutions

Emergent BioSolutions Secures $29 Million in MCM Product Orders from International Government Partner

3 months ago - By: Emergent BioSolutions

Emergent BioSolutions Secures $17 Million Contract Modification for Oral Suspension TEMBEXA® (brincidofovir), a Smallpox Antiviral, and Strengthens Overall U.S. Supply Chain

3 months ago - By: Emergent BioSolutions

Emergent BioSolutions Secures $17 Million Contract Modification for Oral Suspension TEMBEXA® (brincidofovir), a Smallpox Antiviral, and Strengthens Overall U.S. Supply Chain

3 months ago - By: Emergent BioSolutions

Emergent BioSolutions Receives New Contract Modification for ACAM2000®, (Smallpox and Mpox (Vaccinia) Vaccine, Live) from the U.S. Government, Further Demonstrating Importance of Public Health Preparedness

3 months ago - By: Emergent BioSolutions

Emergent BioSolutions Receives New Contract Modification for ACAM2000®, (Smallpox and Mpox (Vaccinia) Vaccine, Live) from the U.S. Government, Further Demonstrating Importance of Public Health Preparedness

3 months ago - By: Emergent BioSolutions

Emergent BioSolutions Awarded $30 Million Contract Modification for CYFENDUS® (Anthrax Vaccine Adsorbed, Adjuvanted), a Two-Dose Anthrax Vaccine for Post-Exposure Prophylaxis Use

3 months ago - By: Emergent BioSolutions

Emergent BioSolutions Awarded $30 Million Contract Modification for CYFENDUS® (Anthrax Vaccine Adsorbed, Adjuvanted), a Two-Dose Anthrax Vaccine for Post-Exposure Prophylaxis Use

3 months ago - By: Emergent BioSolutions

Emergent BioSolutions Underscores Continued Support of Increasing Naloxone Awareness Through Public Education Campaign on International Overdose Awareness Day

3 months ago - By: Emergent BioSolutions

Emergent BioSolutions Underscores Continued Support of Increasing Naloxone Awareness Through Public Education Campaign on International Overdose Awareness Day

3 months ago - By: Emergent BioSolutions

Emergent BioSolutions to Participate in Upcoming Investor Conferences